2021
DOI: 10.1016/j.htct.2021.10.434
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Experimental Chimeric Antigen Receptor (Car) T-Cells Versus Axicabtagene Ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma: Matching Adjusted Indirect Comparisons and Systematic Review

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles